Bioiberica takes part in DCAT Week 2022
After the pandemic interrupted its annually scheduled programme, DCAT Week came back in person from the 21st to the 24th of March 2022.
Heparin Science, Bioiberica's Business Unit specialising in the research, development, production and marketing of the Heparin molecule, has taken part in DCAT Week, held from the 21st to the 24th of March in New York, with the aim of establishing strategic alliances and exploring new business opportunities in the US market.
Hosted by the Drug, Chemical & Associated Technologies Association, DCAT Week is the premier business development event for the American pharmaceutical industry, featuring high-level strategic meetings, networking sessions and educational programmes.
Bioiberica has specialised in Heparin since it was first set up in 1975, becoming the world leader in the production of this active pharmaceutical ingredient. The company now has eight first process plants worldwide, thereby guaranteeing the traceability and quality of end-to-end production, presence throughout the whole life of the product and a process designed to minimise any possibility of biological risk.
To discover more visit: www.heparinscience.com